183 related articles for article (PubMed ID: 12939225)
1. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
[TBL] [Abstract][Full Text] [Related]
2. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
[TBL] [Abstract][Full Text] [Related]
3. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
Delsing DJ; Jukema JW; van de Wiel MA; Emeis JJ; van der Laarse A; Havekes LM; Princen HM
J Cardiovasc Pharmacol; 2003 Jul; 42(1):63-70. PubMed ID: 12827028
[TBL] [Abstract][Full Text] [Related]
8. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
[TBL] [Abstract][Full Text] [Related]
9. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice.
Guo H; Lv H; Tang W; Chi J; Liu L; Xu F; Ji Z; Zhai X; Peng F
Cardiovasc Drugs Ther; 2012 Oct; 26(5):375-82. PubMed ID: 22918601
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD.
Famer D; Wahlund LO; Crisby M
Biochem Biophys Res Commun; 2010 Nov; 402(2):367-72. PubMed ID: 20946880
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
Famer D; Crisby M
Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
[TBL] [Abstract][Full Text] [Related]
13. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Chen J; Li D; Schaefer RF; Mehta JL
J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
16. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
Funderburg NT; Jiang Y; Debanne SM; Storer N; Labbato D; Clagett B; Robinson J; Lederman MM; McComsey GA
Clin Infect Dis; 2014 Feb; 58(4):588-95. PubMed ID: 24253250
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin.
Osaka M; Hagita S; Yoshida M
Biomed Res Int; 2013; 2013():962369. PubMed ID: 23509822
[TBL] [Abstract][Full Text] [Related]
20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
